Clinical trials: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- Condition Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- Funder type Industry (pharma, biotech, devices)
Hematologic Malignancies
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
Evaluate the safety, tolerability and pharmacokinetics of ICP-248 in Combination with Orelabrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Trial name
- NCT06378138
- Testing
- ICP-248, Orelabrutinib
- Where
- 53 sites in China
- Volunteers
- 226 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL
A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 versus Chlorambucil in Patients 65 Years or Older with Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic…
- Trial name
- NCT01722487
- Testing
- Ibrutinib, Chlorambucil
- Where
- 108 sites in United States, Australia and 14 more
- Volunteers
- 269 people
- Sponsor
- Pharmacyclics LLC.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma
The purpose of this study is to evaluate the efficacy and safety of ibrutinib versus rituximab in adult Asia Pacific region patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma…
- Trial name
- NCT01973387
- Testing
- Rituximab, Ibrutinib
- Where
- 26 sites in Australia, China and 2 more
- Volunteers
- 160 people
- Sponsor
- Janssen Research & Development, LLC
Lymphoma, Follicular, Lymphoma, Small Lymphocytic
A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma
Primary Objectives: To document the efficacy of treatment with autologous lymphoma-derived HSPPC-96 of selected patients with indolent lymphoma.
- Trial name
- NCT00081809
- Testing
- autologous human tumor-derived HSPPC-96
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Agenus Inc.
Waldenstrom Macroglobulinemia, Multiple Myeloma
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Part A of this study evaluates iopofosine I 131 (CLR 131) in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic…
- Conditions
- Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- CLOVER-WaM (NCT02952508)
- Testing
- Iopofosine I 131 single dose, Iopofosine I 131 multiple dose, Iopofosine I 131 fractionated dose
- Where
- 52 sites in United States, Australia and 9 more
- Volunteers
- 120 people
- Sponsor
- Cellectar Biosciences, Inc.
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This is a Phase 2, open-label, multicenter study, evaluating the efficacy of venetoclax in participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) either in presence of 17p…
- Trial name
- NCT02966756
- Testing
- Venetoclax
- Where
- 31 sites in Australia, China and 2 more
- Volunteers
- 66 people
- Sponsor
- AbbVie
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
This study will treat patients with CLL/SLL whose disease comes back or is not responding to prior therapy, or if they can not bear side effects of the prior treatment.
- Trial name
- NCT06539182
- Testing
- DZD8586
- Where
- 17 sites in China
- Volunteers
- 155 people
- Sponsor
- Dizal Pharmaceuticals
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
The primary objective of this study is to evaluate the safety of zanubrutinib (also known as BGB-3111) in chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström macroglobulinemia, mantle cell lymphoma, or marginal…
- Conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
- Trial name
- NCT04116437
- Testing
- Zanubrutinib
- Where
- 24 sites in United States
- Volunteers
- 96 people
- Sponsor
- BeiGene
Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
This is a Phase 1 dose-escalation study of PRT1419, a myeloid cell leukemia-1 (MCL-1) inhibitor, in participants with selected relapsed/refractory myeloid or B-cell malignancies.
- Conditions
- Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT05107856
- Testing
- PRT1419, Azacitidine, Venetoclax
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- Prelude Therapeutics Incorporated
CLL/SLL
Global Trial in APG2575 for Patients With CLL/SLL
This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK…
- Trial name
- NCT06104566
- Testing
- lisaftoclax +BTK inhibitor, BTK inhibitor
- Where
- 135 sites in United States, Australia and 17 more
- Volunteers
- 400 people
- Sponsor
- Ascentage Pharma Group Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL)
This study will assess the efficacy, safety and pharmacodynamic markers of the study drug, A6, in patients with CLL and small lymphocytic lymphoma (SLL).
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, CLL, SLL
- Trial name
- NCT02046928
- Testing
- A6
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Ångstrom Pharmaceuticals
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL.
- Trial name
- NCT03331198
- Testing
- JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax
- Where
- 84 sites in United States, Canada
- Volunteers
- 320 people
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
Lymphocytic Leukemia
A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
The purpose of this study is to evaluate the safety of Ibrutinib in Japanese participants with treatment-naive chronic lymphocytic leukemia ( CLL) or small lymphocytic lymphoma (SLL).
- Trial name
- NCT02556892
- Testing
- Ibrutinib
- Where
- 8 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Janssen Pharmaceutical K.K.
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
This phase I trial studies the side effects and best dose of MORAb-004 in treating young patients with recurrent or refractory solid tumors or lymphoma.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Childhood Burkitt Lymphoma
- Trial name
- NCT01748721
- Testing
- anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study, laboratory biomarker analysis
- Where
- 20 sites in United States
- Volunteers
- 27 people
- Sponsor
- Morphotek
EBV-induced Lymphomas, EBV-associated Malignancies
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.
- Conditions
- EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
- Trial name
- NCT00002663
- Testing
- Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Atara Biotherapeutics
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Hematologic Malignancies
GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
The purpose of this study is to assess the impact and safety of itacitinib in combination with calcineurin inhibitor (CNI)-based interventions for the prophylaxis of graft-versus-host-disease (GVHD).
- Trial name
- NCT03320642
- Testing
- Itacitinib, Calcineurin inhibitor
- Where
- 17 sites in United States, France and 2 more
- Volunteers
- 84 people
- Sponsor
- Incyte Corporation
Leukemia, Lymphocytic, Chronic, B-Cell
A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Safety, pharmacokinetics, and preliminary efficacy of CC-122 alone and in combination with ibrutinib and obinuzutumab. CC-122 has multiple activities, including immune modulation of several immune cell subsets and…
- Trial name
- ENHANCE (NCT02406742)
- Testing
- CC-122, Ibrutinib, Obinutuzumab
- Where
- 24 sites in United States, Austria and 3 more
- Volunteers
- 47 people
- Sponsor
- Celgene
Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
The study is a global, multi-center safety and efficacy trial of epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20).
- Conditions
- Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia
- Trial name
- EPCORE™ CLL-1 (NCT04623541)
- Testing
- Epcoritamab, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, Venetoclax
- Where
- 81 sites in United States, Australia and 10 more
- Volunteers
- 194 people
- Sponsor
- Genmab
Hematological Malignancies
Study of IV CBL0137 in Previously Treated Hematological Subjects
This clinical trial is a Phase 1, open-label, sequential-group, dose-escalation (Part 1) and cohort-expansion study (Part 2) evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of intravenously (IV)…
- Trial name
- NCT02931110
- Testing
- CBL0137
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Incuron